BioCentury
ARTICLE | Company News

FDA accepts NDA for Cosmo's antibiotic

May 18, 2018 8:21 PM UTC

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16.

Aemcolo is a broad-spectrum, semisynthetic, oral non-absorbable antibiotic formulated with Multi-Matrix system (MMX) technology...

BCIQ Company Profiles

Cosmo Pharmaceuticals N.V.